Stocks · News reference
Pharming Launches Joenja (Leniolisib) in Japan for APDS Patients Aged 4 and Older, Marking First Global Launch for Children 4 To 11
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwideOrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 5:07 AM
- Checked
- Aug 13, 2026, 5:07 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $38
Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $37 to $38.
Read original at benzingaPharming shares are trading lower after the company reported Q2 financial results and lowered its FY26 sales guidance below analyst estimates.
Read original at benzinga